Envista Holdings Co. (NYSE:NVST) Stock Position Trimmed by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its stake in Envista Holdings Co. (NYSE:NVST - Free Report) by 6.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 559,900 shares of the company's stock after selling 41,300 shares during the quarter. Renaissance Technologies LLC owned approximately 0.33% of Envista worth $10,800,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC lifted its stake in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after buying an additional 1,638 shares during the period. GAMMA Investing LLC raised its holdings in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after acquiring an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista during the 4th quarter worth $53,000. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in shares of Envista during the fourth quarter worth $86,000. Finally, KBC Group NV increased its stake in Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after purchasing an additional 3,082 shares during the last quarter.

Envista Stock Performance

Shares of NYSE NVST traded up $0.32 during trading on Tuesday, reaching $15.19. The stock had a trading volume of 1,770,832 shares, compared to its average volume of 2,491,165. The firm's 50 day moving average price is $17.57 and its two-hundred day moving average price is $19.16. Envista Holdings Co. has a one year low of $14.22 and a one year high of $23.00. The stock has a market cap of $2.61 billion, a PE ratio of -2.34, a P/E/G ratio of 1.27 and a beta of 1.12. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Envista (NYSE:NVST - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on NVST. Needham & Company LLC reiterated a "hold" rating on shares of Envista in a report on Thursday, March 6th. New Street Research set a $19.00 price objective on shares of Envista in a research note on Thursday, March 6th. Piper Sandler raised their price objective on Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Morgan Stanley set a $16.00 price target on shares of Envista in a research report on Tuesday, April 15th. Finally, UBS Group cut their price objective on Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Monday, March 10th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $19.96.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.